WO2012135064A3 - Attenuated strains of plasmodium - Google Patents

Attenuated strains of plasmodium Download PDF

Info

Publication number
WO2012135064A3
WO2012135064A3 PCT/US2012/030443 US2012030443W WO2012135064A3 WO 2012135064 A3 WO2012135064 A3 WO 2012135064A3 US 2012030443 W US2012030443 W US 2012030443W WO 2012135064 A3 WO2012135064 A3 WO 2012135064A3
Authority
WO
WIPO (PCT)
Prior art keywords
plasmodium
attenuated strains
present disclosure
parasites
apicoplast
Prior art date
Application number
PCT/US2012/030443
Other languages
French (fr)
Other versions
WO2012135064A2 (en
Inventor
Joseph L. DERISI
Ellen YEH
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2012135064A2 publication Critical patent/WO2012135064A2/en
Publication of WO2012135064A3 publication Critical patent/WO2012135064A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present disclosure relates to blood-stage malaria parasites. In particular, the present disclosure provides viable malarial parasites that lack an apicoplast as a consequence of conditions under which that are grown.
PCT/US2012/030443 2011-03-25 2012-03-23 Attenuated strains of plasmodium WO2012135064A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161467834P 2011-03-25 2011-03-25
US61/467,834 2011-03-25

Publications (2)

Publication Number Publication Date
WO2012135064A2 WO2012135064A2 (en) 2012-10-04
WO2012135064A3 true WO2012135064A3 (en) 2013-02-14

Family

ID=46932259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/030443 WO2012135064A2 (en) 2011-03-25 2012-03-23 Attenuated strains of plasmodium

Country Status (1)

Country Link
WO (1) WO2012135064A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016069949A1 (en) * 2014-10-29 2016-05-06 Virginia Tech Intellectual Properties, Inc. Compositions and formulations of methylerthritol phosphate pathway inhibitors and uses thereof
MX2018002292A (en) 2015-08-26 2018-08-15 Texas A & M Univ Sys Compositions and methods for drug sensitization of parasites.
WO2018049459A1 (en) * 2016-09-16 2018-03-22 Griffith University Vaccine comprising drug and parasite administration

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185050A1 (en) * 2003-03-12 2004-09-23 Mota Maria M. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
WO2008147826A1 (en) * 2007-05-22 2008-12-04 Seattle Biomedical Research Institute Malaria liver stage drugs
US20100292472A1 (en) * 2008-01-23 2010-11-18 Tomoko Toyama Prophylactic and therapeutic medicine for malaria

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185050A1 (en) * 2003-03-12 2004-09-23 Mota Maria M. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
WO2008147826A1 (en) * 2007-05-22 2008-12-04 Seattle Biomedical Research Institute Malaria liver stage drugs
US20100292472A1 (en) * 2008-01-23 2010-11-18 Tomoko Toyama Prophylactic and therapeutic medicine for malaria

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAHL, E. L. ET AL.: "Tetracyclines Specifically Target the Apicoplast of the Malaria Parasite Plasmodium falciparum", ANTIMICROB AGENTS CHEMOTHER., vol. 50, no. 9, September 2006 (2006-09-01), pages 3124 - 3131 *
HAUSSIG, J. M. ET AL.: "Inactivation of a Plasmodium apicoplast protein att enuates formation of liver merozoites", MOL MICROBIOL., vol. 81, no. 6, September 2011 (2011-09-01), pages 1511 - 1525 *
YEH, E. ET AL.: "Chemical Rescue of Malaria Parasites Lacking an Apicoplast Defines Organelle Function in Blood-Stage Plasmodium falciparum", PLOS BIOL., vol. 9, no. 8, August 2011 (2011-08-01), pages 1 - 10 *

Also Published As

Publication number Publication date
WO2012135064A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
EP2650124A4 (en) Fine-structure laminate, method for preparing fine-structure laminate, and production method for fine-structure laminate
ZA201307876B (en) Genetically engineered microorganisms that metabolize xylose
EP2697289A4 (en) Lignin compositions, methods of producing the compositions, methods of using lignin compositions, and products produced thereby
EP2797126A4 (en) Light-emitting diode, and method for producing same
ZA201400144B (en) Lignin conversion process
EP2730959A4 (en) Optical connection member, optical connection structure, and method for producing optical connection member
PL2674034T3 (en) Method for producing krill oil, and krill oil produced by the method
IL238401A0 (en) Pichia pastoris strains for producing predominantly homogeneous glycan structure
ZA201307238B (en) Lifting beam
WO2012082731A3 (en) Engineered microalgae with enhanced lipid production
HK1199199A1 (en) Blood stage malaria vaccine
WO2012064743A3 (en) Methods for improving heart function
EP2597152A4 (en) Genetically engineered strain wsj-ia for producing isovaleryl spiramycin i.
EP2514735A4 (en) Method for producing 3,3,3-trifluoro propene
WO2012135064A3 (en) Attenuated strains of plasmodium
ZA201403950B (en) Vaccine for falciparum malaria
WO2011110624A3 (en) β-HYDROXYALKYLAMIDES, METHOD FOR THEIR PRODUCTION AND USE THEREOF
EP2780462A4 (en) Engineered pichia strains with improved fermentation yield and n-glycosylation quality
GB201103470D0 (en) Potato tower
ZA201404512B (en) Malaria vaccine
IL229316B (en) Genetically engineered growth factor variants
EP2688586A4 (en) Plasmodium falciparum antigens
EP2825658A4 (en) Genetically modified plants having improved saccharification properties
AU2011901274A0 (en) Improved Connecting Method
AU2011903067A0 (en) Engineered cellulosic products

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12763719

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12763719

Country of ref document: EP

Kind code of ref document: A2